Dispersible formulation of an anti-inflammatory agent
First Claim
1. A method of treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, the method comprising administering a pharmaceutical composition comprising an anti-inflammatory agent to the organ via the exterior orifice, said composition further comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier;
- and administering in combination therapy with said anti-inflammatory agent a second agent selected from the group consisting of antibacterial agents, analgesics, antipyretics, anesthetics, sodium channel blockers, antineoplastic agents, and antiedemic agents, wherein the second agent is administered by a route other than the route of administration of the anti-inflammatory agent.
0 Assignments
0 Petitions
Accused Products
Abstract
A method is provided for treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and a process for preparing such a composition.
-
Citations
67 Claims
-
1. A method of treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, the method comprising administering a pharmaceutical composition comprising an anti-inflammatory agent to the organ via the exterior orifice, said composition further comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier;
- and administering in combination therapy with said anti-inflammatory agent a second agent selected from the group consisting of antibacterial agents, analgesics, antipyretics, anesthetics, sodium channel blockers, antineoplastic agents, and antiedemic agents, wherein the second agent is administered by a route other than the route of administration of the anti-inflammatory agent.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
15. A method of treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, the method comprising administering a pharmaceutical composition comprising an anti-inflammatory agent to the organ via the exterior orifice, said composition further comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier;
- and said composition further comprising a second agent selected from the group consisting of analgesics, antipyretics, anesthetics, sodium channel blockers, antineoplastic agents, and antiedemic agents.
-
28. A pharmaceutical composition comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier;
- said vehicle having stably dispersed therein an anti-inflammatory agent in an anti-inflammatorily effective amount, and further comprising a second agent selected from the group consisting of analgesics, antipyretics, anesthetics, sodium channel blockers, antineoplastic agents, and antiedemic agents.
- View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)
Specification